| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $191K | — | — |
| SG&A Expense | $1.6M | — | +13.7% |
| Operating Income | -$8.2M | — | -17.6% |
| Net Income | -$8.2M | — | -38.8% |
| EPS (Basic) | -$0.47 | — | -12.0% |
| EPS (Diluted) | -$0.47 | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $39.6M | +0.3% | -46.6% |
| Current Assets | $46.5M | -18.1% | -48.4% |
| Total Assets | $484.2M | +8.4% | +27.0% |
| Current Liabilities | $50.3M | +37.5% | +45.0% |
| Total Liabilities | $68.8M | +20.7% | +27.0% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$13.8M | — | -232.2% |
| Investing Cash Flow | -$28.4M | — | -96.2% |
| Financing Cash Flow | $37.9M | — | +126.6% |
| $295.1M |
| +2.6% |
| +7.1% |